2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan

Yi Heng Li; Chih Yuan Fang; I. Chang Hsieh; Wei Chun Huang; Tsung Hsien Lin; Shih Hsien Sung; Chiung Zuan Chiu; Chiung Jen Wu; Kou Gi Shyu; Po Yuan Chang; Ching Chang Fang; Tse Min Lu; Ching Pei Chen; Wei Chen Tai; Chau Chyun Sheu; Kai Che Wei; Yi Hsiu Huang; Hsing Mei Wu; Juey Jen Hwang

doi:10.6515/ACS.201805_34(3).20180302A

2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan

Yi Heng Li, Chih Yuan Fang, I. Chang Hsieh, Wei Chun Huang, Tsung Hsien Lin, Shih Hsien Sung, Chiung Zuan Chiu, Chiung Jen Wu, Kou Gi Shyu, Po Yuan Chang, Ching Chang Fang, Tse Min Lu, Ching Pei Chen, Wei Chen Tai, Chau Chyun Sheu, Kai Che Wei, Yi Hsiu Huang, Hsing Mei Wu, Juey Jen Hwang

內科學科

研究成果: Review article › 同行評審

17 引文斯高帕斯（Scopus）

摘要

Antiplatelet therapy is a key component in the treatment of acute coronary syndrome (ACS). The management of ACS has evolved considerably over recent years with the development of new and more potent antiplatelet agents. Clinical trials on ACS have demonstrated that potent antiplatelet agents can more effectively reduce cardiovascular events. However, there is a tipping point between safety and efficacy, beyond which the risk of bleeding and other adverse effects can outweigh the benefits of antiplatelet therapy. Striking a balance between safety and efficacy remains a major challenge. A consensus meeting of an expert panel composed of Taiwanese experts was held to provide recommendations for the management of adverse effects in patients with ACS receiving antiplatelet therapy. The common adverse effects of antiplatelet therapy include upper gastrointestinal bleeding, ecchymosis, hematuria, epistaxis and ticagrelor-related dyspnea. In this study, a literature review of these adverse events was performed and recommendations for the management were made.

原文	English
頁（從 - 到）	201-210
頁數	10
期刊	Acta Cardiologica Sinica
卷	34
發行號	3
DOIs	https://doi.org/10.6515/ACS.201805_34(3).20180302A
出版狀態	Published - 2018 5月

All Science Journal Classification (ASJC) codes

心臟病學與心血管醫學

存取文件

10.6515/ACS.201805_34(3).20180302A

其它文件與鏈接

引用此

Li, Y. H., Fang, C. Y., Hsieh, I. C., Huang, W. C., Lin, T. H., Sung, S. H., Chiu, C. Z., Wu, C. J., Shyu, K. G., Chang, P. Y., Fang, C. C., Lu, T. M., Chen, C. P., Tai, W. C., Sheu, C. C., Wei, K. C., Huang, Y. H., Wu, H. M., & Hwang, J. J. (2018). 2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan. Acta Cardiologica Sinica, 34(3), 201-210. https://doi.org/10.6515/ACS.201805_34(3).20180302A

@article{fc76ce25a6654014905a5222854db448,

title = "2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan",

abstract = "Antiplatelet therapy is a key component in the treatment of acute coronary syndrome (ACS). The management of ACS has evolved considerably over recent years with the development of new and more potent antiplatelet agents. Clinical trials on ACS have demonstrated that potent antiplatelet agents can more effectively reduce cardiovascular events. However, there is a tipping point between safety and efficacy, beyond which the risk of bleeding and other adverse effects can outweigh the benefits of antiplatelet therapy. Striking a balance between safety and efficacy remains a major challenge. A consensus meeting of an expert panel composed of Taiwanese experts was held to provide recommendations for the management of adverse effects in patients with ACS receiving antiplatelet therapy. The common adverse effects of antiplatelet therapy include upper gastrointestinal bleeding, ecchymosis, hematuria, epistaxis and ticagrelor-related dyspnea. In this study, a literature review of these adverse events was performed and recommendations for the management were made.",

author = "Li, {Yi Heng} and Fang, {Chih Yuan} and Hsieh, {I. Chang} and Huang, {Wei Chun} and Lin, {Tsung Hsien} and Sung, {Shih Hsien} and Chiu, {Chiung Zuan} and Wu, {Chiung Jen} and Shyu, {Kou Gi} and Chang, {Po Yuan} and Fang, {Ching Chang} and Lu, {Tse Min} and Chen, {Ching Pei} and Tai, {Wei Chen} and Sheu, {Chau Chyun} and Wei, {Kai Che} and Huang, {Yi Hsiu} and Wu, {Hsing Mei} and Hwang, {Juey Jen}",

note = "Funding Information: was held by AstraZeneca Taiwan. This work was supported by AstraZeneca Taiwan. The authors would like to thank Mr. Kevin Hung, AstraZeneca Taiwan for his administrative support. The funders had no role in the publication of this study. Publisher Copyright: {\textcopyright} 2018, Republic of China Society of Cardiology. All rights reserved.",

year = "2018",

month = may,

doi = "10.6515/ACS.201805_34(3).20180302A",

language = "English",

volume = "34",

pages = "201--210",

journal = "Acta Cardiologica Sinica",

issn = "1011-6842",

publisher = "Republic of China Society of Cardiology",

number = "3",

}

Li, YH, Fang, CY, Hsieh, IC, Huang, WC, Lin, TH, Sung, SH, Chiu, CZ, Wu, CJ, Shyu, KG, Chang, PY, Fang, CC, Lu, TM, Chen, CP, Tai, WC, Sheu, CC, Wei, KC, Huang, YH, Wu, HM & Hwang, JJ 2018, '2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan', Acta Cardiologica Sinica, 卷 34, 編號 3, 頁 201-210. https://doi.org/10.6515/ACS.201805_34(3).20180302A

TY - JOUR

T1 - 2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan

AU - Li, Yi Heng

AU - Fang, Chih Yuan

AU - Hsieh, I. Chang

AU - Huang, Wei Chun

AU - Lin, Tsung Hsien

AU - Sung, Shih Hsien

AU - Chiu, Chiung Zuan

AU - Wu, Chiung Jen

AU - Shyu, Kou Gi

AU - Chang, Po Yuan

AU - Fang, Ching Chang

AU - Lu, Tse Min

AU - Chen, Ching Pei

AU - Tai, Wei Chen

AU - Sheu, Chau Chyun

AU - Wei, Kai Che

AU - Huang, Yi Hsiu

AU - Wu, Hsing Mei

AU - Hwang, Juey Jen

N1 - Funding Information: was held by AstraZeneca Taiwan. This work was supported by AstraZeneca Taiwan. The authors would like to thank Mr. Kevin Hung, AstraZeneca Taiwan for his administrative support. The funders had no role in the publication of this study. Publisher Copyright: © 2018, Republic of China Society of Cardiology. All rights reserved.

PY - 2018/5

Y1 - 2018/5

N2 - Antiplatelet therapy is a key component in the treatment of acute coronary syndrome (ACS). The management of ACS has evolved considerably over recent years with the development of new and more potent antiplatelet agents. Clinical trials on ACS have demonstrated that potent antiplatelet agents can more effectively reduce cardiovascular events. However, there is a tipping point between safety and efficacy, beyond which the risk of bleeding and other adverse effects can outweigh the benefits of antiplatelet therapy. Striking a balance between safety and efficacy remains a major challenge. A consensus meeting of an expert panel composed of Taiwanese experts was held to provide recommendations for the management of adverse effects in patients with ACS receiving antiplatelet therapy. The common adverse effects of antiplatelet therapy include upper gastrointestinal bleeding, ecchymosis, hematuria, epistaxis and ticagrelor-related dyspnea. In this study, a literature review of these adverse events was performed and recommendations for the management were made.

AB - Antiplatelet therapy is a key component in the treatment of acute coronary syndrome (ACS). The management of ACS has evolved considerably over recent years with the development of new and more potent antiplatelet agents. Clinical trials on ACS have demonstrated that potent antiplatelet agents can more effectively reduce cardiovascular events. However, there is a tipping point between safety and efficacy, beyond which the risk of bleeding and other adverse effects can outweigh the benefits of antiplatelet therapy. Striking a balance between safety and efficacy remains a major challenge. A consensus meeting of an expert panel composed of Taiwanese experts was held to provide recommendations for the management of adverse effects in patients with ACS receiving antiplatelet therapy. The common adverse effects of antiplatelet therapy include upper gastrointestinal bleeding, ecchymosis, hematuria, epistaxis and ticagrelor-related dyspnea. In this study, a literature review of these adverse events was performed and recommendations for the management were made.

UR - http://www.scopus.com/inward/record.url?scp=85047087310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047087310&partnerID=8YFLogxK

U2 - 10.6515/ACS.201805_34(3).20180302A

DO - 10.6515/ACS.201805_34(3).20180302A

M3 - Review article

AN - SCOPUS:85047087310

SN - 1011-6842

VL - 34

SP - 201

EP - 210

JO - Acta Cardiologica Sinica

JF - Acta Cardiologica Sinica

IS - 3

ER -

2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan

摘要

All Science Journal Classification (ASJC) codes

存取文件

其它文件與鏈接

指紋

引用此